Recruiting

NCT Number: NCT06742021

Application of DCE-MRI Based on 4D FreeBreathing in Predicting the Efficacy of Immune and Targeted Therapy in Lung Cancer

This study aims to address the challenge of predicting the efficacy of targeted and immunotherapy in lung cancer patients. By utilizing two DCE-MRI images-one before treatment and one after one treatment cycle-along with the patients' clinical and pathological information, we aim to achieve accurate prediction of the therapeutic efficacy of targeted and immunotherapy in lung cancer patients.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Lung Cancer Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Yunnan Cancer Hospital

Kunming, Yunnan, China

Location status: Recruiting

Location contact

Guojun Zhang

CONTACT

r 0871-68173640

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Tumor size greater than 2 cm
Age between 18 and 75 years

Exclusion criteria

Presence of MRI contraindications (e.g., metal implants, pacemaker implantation, etc.)
Allergy to gadolinium contrast agents
Lesions difficult to delineate on images due to conditions such as atelectasis or diffuse lesions

Treatment and study plan

Application Value of MRI Imaging in Treatment Decision-Making for Lung Cancer

Diagnostic Test

Chest MRI scans outside of the standard treatment protocol

Primary outcomes

Tumor treatment response evaluation

Time frame: within one week before treatment and two weeks after treatment completion

This study aims to evaluate tumor treatment response using the RECIST V1.1 criteria, based on CT images taken within one week before treatment and two weeks after treatment completion.

Study contacts

Contact information is provided by the study sponsor or research team.

Zhenhui Li

CONTACT

[email protected]

13698736132

zhihui shi

CONTACT

[email protected]

15087838660

Sponsors and collaborators

Lead sponsor

Yunnan Cancer Hospital

Other

Registry information

Important dates

Study start: 2024
Primary completion: 2026
Study completion: 2026
First posted: Dec 19, 2024
Registry last updated: Dec 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting